Kári Stefánsson
Chairman
Kári Stefánsson, M.D., Dr. Med. has served as our President, Chief Executive Officer and a Director since he co-founded deCODE in August 1996. Dr. Stefánsson was appointed to serve as the Chairman of our Board of Directors in December 1999. From 1993 until April 1997, Dr. Stefánsson was a professor of Neurology, Neuropathology and Neuroscience at Harvard University. In addition, from 1993 through December 1996 he was Director of Neuropathology at Beth Israel Hospital in Boston, Massachusetts. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Dr. Stefánsson received his M.D. and Dr. Med. from the University of Iceland and is board-certified in neurology and neuropathology in the United States.
Dr. Stefansson is a Class III director and his term expires in 2010.
J. Neal Armstrong
Director
J. Neal Armstrong has served as a director since October 2003. Mr. Armstrong serves as a Chairman of the Company’s Audit Committee and is a member of the Compensation Committee.
Mr. Armstrong served as Vice President, Chief Financial Officer, Secretary and Treasurer of Aspect Medical Systems, Inc., a developer and manufacturer of an anesthesia monitoring system from 1996 until his retirement in 2006. Effective January 1, 2009, Neal Armstrong rejoined Aspect assuming his former role as Vice President, Chief Financial Officer and Secretary. From 1990 to 1996, Mr. Armstrong served as Vice President of Finance, Chief Financial Officer and as a director of Haemonetics, Inc., a manufacturer of blood processing systems. From 1985 to 1990, he was the Vice President of Finance and Administration, Treasurer and Chief Financial Officer at BTU International, a manufacturer of thermal processing systems. Prior to 1985, he served for 14 years in senior operating and financial positions at Texas Instruments, Inc., an electronics company.
Mr. Armstrong is a Class II director and his term expires in 2009.
James BeeryDirector 
James Beery joined the board of deCODE genetics in May 2004. Mr. Beery serves as a Chairman of the Company’s Nominating and Corporate Governance Committee and is a member of the Audit Committee.
Mr. Beery is Senior Of Counsel in the London office of Covington & Burling, an international law firm. Prior to his retirement in 2001, Mr. Beery served as Senior Vice President and General Counsel of GlaxoSmithKline PLC, a UK-based global pharmaceutical company. From 1993 until the formation of the merged company GlaxoSmithKline, Mr. Beery served as Senior Vice President, General Counsel and Secretary of SmithKline Beecham PLC. Mr. Beery holds a BA from Harvard College and a JD from Stanford Law School. He is currently a director of Martek Biosciences, Inc., Orchid Cellmark, Inc., Inion OY and the London Centre for the International Education of Students, and is a member of the Board of Visitors of Stanford Law School and the Advisory Board of the Stanford Law School Program in Law, Science and Technology.
Mr. Beery is a Class II director and his term expires in 2009.
Earl M. Collier,
Jr
Director
Mr. Earl M. "Duke" Collier, Jr joined the board of deCODE genetics in July 2006. Mr. Collier serves as the Chairman of the Company’s Compensation Committee.
Mr. Collier is an Executive Vice President at Genzyme Corp. He has previously served as President of Vitas Healthcare, was a partner at the Washington, DC-based law firm of Hogan and Hartson, and served as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier received his BA from Yale University and his JD from the University of Virginia. He serves on the Board of Directors of Pervasis Therapeutics, a private company in Cambridge, Massachusetts, and Newton Wellesley Hospital.
Mr. Collier is a Class II director and his term expires in 2009.
Peter Goodfellow
Director
Peter Goodfellow
Director
Peter Goodfellow joined the board of deCODE genetics in September 2006 and is a member of the Company’s Compensation Committee.
Dr Goodfellow has held senior management positions at GlaxoSmithKline and SmithKline Beecham. Previously, he held the Balfour chair in genetics at Cambridge University and research positions at the Imperial Cancer Research Fund. Dr. Goodfellow received his doctorate from Oxford University and held a postdoctoral fellowship at Stanford University. He is a Fellow of the Royal Society and has been awarded several scientific prizes for pioneering research in human genetics.
Dr. Goodfellow is a Class III director and his term expires in 2010.
